scholarly article | Q13442814 |
P356 | DOI | 10.1161/01.CIR.97.22.2230 |
P698 | PubMed publication ID | 9631872 |
P50 | author | Michel Komajda | Q64498753 |
P2093 | author name string | Richard P | |
Charron P | |||
Hainque B | |||
Camproux AC | |||
Dubourg O | |||
Schwartz K | |||
Carrier L | |||
Isnard R | |||
Bonne G | |||
Bouhour JB | |||
Desnos M | |||
Bennaceur M | |||
Langlard JM | |||
Hagege A | |||
P433 | issue | 22 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | familial hypertrophic cardiomyopathy | Q56014654 |
hypertrophic cardiomyopathy | Q1364270 | ||
P304 | page(s) | 2230-2236 | |
P577 | publication date | 1998-06-01 | |
P1433 | published in | Circulation | Q578091 |
P1476 | title | Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene | |
P478 | volume | 97 |
Q91359304 | A novel MYBPC3 c.2737+1 (IVS26) G>T mutation responsible for high-risk hypertrophic cardiomyopathy |
Q77616527 | A novel deletion mutation in the cardiac myosin-binding protein C gene as a cause of Maron's type IV hypertrophic cardiomyopathy |
Q28182167 | A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients |
Q57907349 | Acquis et perspective de la génétique des myocardiopathies |
Q33379935 | Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene |
Q38295649 | Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice |
Q34275552 | American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the Euro |
Q34286730 | Clinical and echocardiographic features of hypertrophic cardiomyopathy in the elderly |
Q64997486 | Clinicopathological and Genetic Profiles of Cases with Myocytes Disarray-Investigation for Establishing the Autopsy Diagnostic Criteria for Hypertrophic Cardiomyopathy. |
Q37629210 | Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy |
Q74353552 | Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations |
Q24681653 | Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy |
Q30328020 | Effects of a cardiomyopathy-causing troponin t mutation on thin filament function and structure. |
Q34430364 | FHL2 expression and variants in hypertrophic cardiomyopathy |
Q37672736 | Familial hypertrophic cardiomyopathy associated with a new mutation in gene MYBPC3. |
Q28283579 | Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands |
Q77429816 | Genes and disease expression in hypertrophic cardiomyopathy |
Q34673385 | Genes and their polymorphisms in mono- and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure |
Q35145962 | Genetic advances in sarcomeric cardiomyopathies: state of the art. |
Q36712985 | Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing |
Q37786123 | Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases |
Q37125766 | Genetic determinants of cardiac hypertrophy |
Q37766140 | Genetic evaluation of familial cardiomyopathy |
Q38058475 | Genetic testing in the contemporary diagnosis of cardiomyopathy |
Q57907337 | Génétique des cardiomyopathies hypertrophiques |
Q28138779 | Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C |
Q82093356 | Hypertrophic cardiomyopathy |
Q45339581 | Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage |
Q33147359 | Hypertrophic cardiomyopathy complicated by severe bradycardias: a pedigree report |
Q42339402 | Hypertrophic cardiomyopathy in daily practice: an introduction on diagnosis, prognosis and treatment |
Q38203157 | Hypertrophic cardiomyopathy: how do mutations lead to disease? |
Q35113389 | Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion |
Q33167969 | Hypertrophic obstructive cardiomyopathy |
Q46348368 | Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy. |
Q77947888 | Late-onset primary LVH HCM versus cardiac fabry variant |
Q37101872 | MYBPC3 gene variations in hypertrophic cardiomyopathy patients in India |
Q37949516 | Mechanisms of disease: hypertrophic cardiomyopathy |
Q34641881 | Modifier genes for hypertrophic cardiomyopathy |
Q34469735 | Molecular genetic basis of sudden cardiac death |
Q34021080 | Molecular genetics and pathogenesis of hypertrophic cardiomyopathy |
Q36344118 | Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease |
Q34027457 | Molecular genetics of hypertrophic cardiomyopathy |
Q36299735 | Multiple forms of cardiac myosin-binding protein C exist and can regulate thick filament stability |
Q37490943 | Mutation Analysis of Three Exons of Myosin-Binding Protein C3 in Patients with Hypertrophic Cardiomyopathy |
Q44354566 | Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy |
Q51149024 | Myocardial Scar Visualized by Cardiovascular Magnetic Resonance Imaging Predicts Major Adverse Events in Patients With Hypertrophic Cardiomyopathy |
Q34028344 | Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy |
Q33145751 | Natural history of hypertrophic cardiomyopathy |
Q34445272 | Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy |
Q42735759 | On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture |
Q39367648 | Recent advances in genetics and treatment of hypertrophic cardiomyopathy |
Q35580191 | Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy |
Q73682058 | Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy |
Q34759446 | Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. |
Q33158326 | Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers |
Q36369925 | Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes |
Q35758994 | Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing |
Q33569089 | Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy |
Q52962652 | Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. |
Q33148988 | Subclinical skeletal muscle abnormalities in patients with hypertrophic cardiomyopathy and their relation to clinical characteristics |
Q44057427 | T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. |
Q35743765 | The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy |
Q77096691 | The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited |
Q33942334 | The genomics of cardiovascular disorders: therapeutic implications |
Q57907347 | The heart of genomics |
Q33939892 | The molecular genetic basis for hypertrophic cardiomyopathy |
Q35771667 | The pathology of hypertrophic cardiomyopathy |
Q64232857 | Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations |
Q42748756 | To screen or not is not the question--it is when and how to screen |
Q36057314 | Toward Personalized Medicine: Does Genetic Diagnosis of Pediatric Cardiomyopathy Influence Patient Management? |
Q34425285 | Two novel mutations of the MYBPC3 gene identified in Chinese families with hypertrophic cardiomyopathy |
Q82388219 | Use of genetics in the clinical evaluation and management of heart failure |
Q74430979 | Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy |
Q31158025 | Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data |
Q36366148 | Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation |
Q52936185 | [Cardiomyopathies II. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy]. |
Q74043611 | [Genetically modified animal models in cardiovascular research] |
Search more.